Tolerability of fosamprenavir/ritonavir associated with zidovudine-lamivudine used as postexposure prophylaxis for HIV infection.
Burty
Christine
C
Pavel
Simona
S
Ghomari
Kamel
K
Vermersch
Annie
A
Christian
Bernard
B
Pouaha
Jean
J
Yazdanpanah
Yazdan
Y
May
Thierry
T
Rabaud
Christian
C
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D002219:Carbamates / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D005663:Furans; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D010755:Organophosphates / Q000008:administration & dosage / Q000009:adverse effects*; D011446:Prospective Studies; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*; D015215:Zidovudine / Q000008:administration & dosage / Q000009:adverse effects*
D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D010755:Organophosphates; D013449:Sulfonamides; D019259:Lamivudine; D015215:Zidovudine; D019438:Ritonavir; C426859:fosamprenavir